文献速递心力衰竭与心肌病

司美格鲁肽在实验性HFpEF中独立于减重改善心脏与肝脏重构

Semaglutide, independent of weight loss, attenuates cardiac and hepatic remodelling in experimental heart failure with preserved ejection fraction.
PubMed 文献 · Eur Heart J · 2026-10-05

本研究在ZSF1肥胖大鼠和Göttingen小型猪两种肥胖相关代谢性HFpEF模型中,采用不引起显著减重的司美格鲁肽剂量进行干预。结果显示,司美格鲁肽可在无显著体重下降的情况下改善舒张功能、减轻心脏肥厚与纤维化、减少心脏和肝脏异位脂质沉积,并能逆转已建立HFpEF小型猪的舒张功能障碍及晚期肝桥接纤维化。机制上,多组学分析提示其通过抑制促纤维化和促肥厚信号、上调心肌细胞支链氨基酸分解代谢与脂肪酸氧化通路发挥作用。

要点

  • 司美格鲁肽在不引起显著减重的剂量下即可改善HFpEF模型舒张功能。
  • 获益包括减轻心脏肥厚与纤维化、减少心肌和肝脏异位脂质沉积。
  • 机制涉及抑制促纤维化/促肥厚信号并上调心肌BCAA分解与脂肪酸氧化。

核心结论

  • 司美格鲁肽在无显著体重下降的情况下可减轻肥胖相关代谢性HFpEF临床前模型的心脏和肝脏重构。
  • 效果在雄性啮齿类与雌性猪模型中一致,支持其转化相关性。

研究设计与样本

  • 雄性ZSF1肥胖大鼠每组12只,给予经经验确定不引起减重的司美格鲁肽剂量。
  • 雌性Göttingen小型猪采用『两次打击』诱导HFpEF,早期干预每组5只、延迟干预每组4只。
  • 评估包括有创血流动力学(LVEDP、PCWP)、超声心动图以及纤维化和脂质负荷的组织学定量。
  • 延迟干预采用心脏MRI定量皮下及异位脂肪库。
  • 大鼠中进行NULISA血浆蛋白质组学、单细胞RNA测序和组织蛋白质组学等多组学分析。

主要发现

  • ZSF1肥胖大鼠中,司美格鲁肽在无显著减重情况下使LVEDP降低约60%,心脏肥厚减轻约30%。
  • 大鼠中间质纤维化和心脏脂质沉积也得到减轻。
  • 小型猪HFpEF模型中,司美格鲁肽减轻心脏肥厚和左心室E/e',并使PCWP恢复正常。
  • 小型猪中司美格鲁肽逆转了晚期肝桥接纤维化。
  • 已建立HFpEF的小型猪经延迟干预后舒张功能障碍逆转,心肌内、心外膜和肝脏脂肪显著减少。

关键数值与推荐

  • ZSF1肥胖大鼠LVEDP降低约60%,心脏肥厚减轻约30%。
  • 小型猪中左心室E/e'降低、PCWP恢复正常,晚期肝桥接纤维化逆转。
  • 延迟干预显著减少心肌内、心外膜和肝脏异位脂肪,但不影响皮下脂肪和总体重。

临床怎么用

  • 研究结果支持在肥胖相关代谢性HFpEF表型中进一步探索GLP-1受体激动剂的减重非依赖性信号机制。
  • 未来研究需确定剂量等效性并确认心脏和肝脏组织中GLP-1受体的参与。

局限性

  • 采用不引起减重的经验性剂量,尚需确定与临床剂量的等效性。
  • 研究未直接确认心脏和肝脏组织中GLP-1受体的参与。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Heart failure with preserved ejection fraction (HFpEF) remains a significant therapeutic challenge. While GLP-1 receptor agonists (GLP-1RAs) show clinical promise, it remains unknown if their benefits are driven solely by weight loss or involve weight loss-independent mechanisms. We investigated the weight loss-independent effects of semaglutide in two preclinical models of cardiometabolic HFpEF: the ZSF1 Obese rat and the Göttingen HFpEF minipig. METHODS: Male ZSF1 Obese rats (n = 12/group) and female Göttingen minipigs with 'two-hit' induced HFpEF (early intervention: n = 5/group; delayed intervention: n = 4/group) were treated with semaglutide at doses empirically determined to be non-weight-loss inducing. Comprehensive assessments included invasive hemodynamic (LVEDP, PCWP), echocardiography, and histological quantification of fibrosis and lipid burden. Delayed intervention utilized Cardiac MRI to quantify subcutaneous and ectopic fat depots. In rats, advanced multi-omics (NULISA plasma proteomics, single-cell RNA sequencing and tissue proteomics) were utilized to explore molecular mechanisms. RESULTS: In ZSF1 Obese rats, semaglutide significantly improved diastolic function (reducing LVEDP by ∼60%) and attenuated cardiac hypertrophy (by ∼30%), interstitial fibrosis, and cardiac lipid deposition in the absence of a significant weight loss. These functional benefits were conserved in the minipig HFpEF model, where treatment attenuated cardiac hypertrophy, left ventricular E/e', normalized pulmonary capillary wedge pressure (PCWP) and reversed advanced hepatic bridging fibrosis. Delayed intervention in established HFpEF minipigs reversed diastolic dysfunction and significantly reduced ectopic lipid depots (intramyocardial, epicardial, and hepatic fat) without affecting subcutaneous fat or total body weight. Mechanistically, multi-omics analyses in the rat heart revealed that these benefits were driven by suppression of pro-fibrotic and hypertrophic signals and up-regulation of branched-chain amino acid (BCAA) catabolism and fatty acid oxidation pathways in cardiomyocytes. CONCLUSIONS: Semaglutide attenuates cardiac and hepatic remodelling in preclinical models of obesity-associated cardiometabolic HFpEF in the absence of profound weight loss. The conservation of these effects across male rodents and female swine supports their translational relevance, while future studies are needed to define dose equivalence and confirm GLP-1 receptor engagement in cardiac and hepatic tissues. These findings support further mechanistic investigation of weight loss-independent GLP-1 receptor agonist signalling in this HFpEF phenotype.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Elbatreek, Li, Yu, et al. Semaglutide, independent of weight loss, attenuates cardiac and hepatic remodelling in experimental heart failure with preserved ejection fraction. Eur Heart J. 2026. PMID: 42830666. doi:10.1093/eurheartj/ehag732

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。